Dive into the twisted and intricate narratives of these 10 horror games that will leave you questioning everything.

Subscribe to LA Public Press to get stories like this in your inbox every week. Bystanders are becoming first responders, ...

This study aims to improve survival modeling in head and neck cancer (HNC) by integrating patient-reported outcomes (PROs) using dimensionality reduction techniques. PROs capture symptom severity ...

The first person to have their name called in this past year’s draft has finally signed her first contract. On Monday, the New York Sirens announced that the team has signed forward Kristýna ...

AUSTIN, Texas — A bill requiring outdoor warning sirens in flash flood-prone areas of Texas is headed to Gov. Greg Abbott's desk after receiving final approval from ...

PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

Fahy is nominated in the best lead actress in a limited or anthology series or movie category for her role in the Netflix show. By Katherine Schaffstall Meghann Fahy was just as surprised as fans when ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...

The New York Sirens have hired Valérie Bois as the team's newest assistant coach ahead of the 2025-26 PWHL season. Bois was the head coach at Bishop's University last season where she guided Bishop's ...

All the Latest Game Footage and Images from Sirenhead: Southpoint Sirenhead: Southpoint, a Survival Horror game that takes place in the 1980’s as you, Freddy Anderson try to go camping with your ...

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...